Tyra Biosciences 8-K: Q3 2025 results press release furnished

Tyra Biosciences, Inc. filed an 8-K announcing it issued a press release covering financial results for the quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/05/2025 - 04:08 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Tyra Biosciences, Inc. filed an 8-K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.

Consistent with General Instruction B.2, the information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The filing lists the company’s common stock under the symbol TYRA on the Nasdaq Global Select Market.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TYRA disclose in this 8-K?

TYRA furnished a press release announcing financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1.

When was the 8-K filed by TYRA?

The company filed the report on November 5, 2025.

Which period do the results cover for TYRA (NASDAQ: TYRA)?

The press release covers the quarter ended September 30, 2025.

Is the press release considered filed or furnished?

It is furnished under General Instruction B.2 and not deemed filed under the Exchange Act.

What exhibit contains the press release for TYRA?

The press release is included as Exhibit 99.1.

What is TYRA’s trading symbol and exchange?

TYRA’s common stock trades under TYRA on the Nasdaq Global Select Market.

Who signed the report for Tyra Biosciences?

It was signed by Alan Fuhrman, Chief Financial Officer, on November 5, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001863127false00018631272025-11-052025-11-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 05, 2025

Tyra Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40800	83-1476348
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2656 State Street
Carlsbad, California				92008
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (619) 728-4760

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		TYRA		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release Issued on November 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			TYRA BIOSCIENCES, INC.
Date:	November 5, 2025	By:	/s/ Alan Fuhrman
			Alan Fuhrman Chief Financial Officer